FDA panel backs Celebrex to treat juvenile RA

Share this article:
An FDA advisory panel recommended that Pfizer’s Celebrex be approved to treat rheumatoid arthritis (RA) in children. The panel of outside experts voted 15-1 in favor of using Celebrex in juvenile patients with RA, suggesting adverse events are closely monitored over the long term. The FDA is not required to follow the panel’s advice but usually does so. Celebrex has faced concerns over its potential to increase heart risks among patients ever since the 2004 withdrawal of Merck’s Vioxx and Pfizer’s Bextra. Following the Vioxx withdrawal, Pfizer continued to sell Celebrex and changed its warning label to include information about potential cardiovascular risks. Celebrex is currently approved for the treatment of RA in adult patients. Approximately 30,000 to 60,000 children in the US suffer from RA.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.